王梦龙
心内
副主任医师，硕士生导师
副主任医师，硕士生导师
导师介绍
| 姓名 | 王梦龙 |
| 出生年月 | 1989年11月 |
| 单位 | 武汉大学人民医院心血管内科 |
| 所属学科 | 临床医学-内科学 |
| 职务、职称及头衔 | 副主任医师，硕士生导师 |
| whuwangmenglong@163.com | |
| 联系方式 | 15827526356 |
| 研究方向 | 1.炎症消退在心血管疾病中的作用及机制研究；2.中枢神经免疫调控心血管疾病的机制研究 |
| 个人简介 | |
| 主要从事心血管疾病的基础与临床研究，主持国家自然科学基金青年项目、湖北省自然科学基金项目、中央高校基本科研业务费专项资金项目各1项，参与国家自然科学基金、湖北省自然科学基金等项目10余项；以第一(含共同第一)及通讯(含共同通讯)作者发表SCI论文30余篇；获湖北省科技进步奖一等奖和二等奖各1项。 | |
| 学术任职与荣誉 | |
|
武汉医学会心血管病学分会第十九届委员 武汉医学会第十九届心血管病学分会第一届高血压学组委员兼秘书 |
|
| 教育履历 | |
|
2007.09-2012.06 武汉大学第一临床学院临床医学获学士学位 2012.09-2015.06 武汉大学第一临床学院内科学获硕士学位 2015.09-2018.06 武汉大学第一临床学院内科学获博士学位 2017.06-2018.06 美国加州大学洛杉矶分校访问学者 |
|
| 工作履历 | |
|
2018.07-2018.11 武汉大学人民医院心血管内科住院医师 2018.12-2020.06 武汉大学人民医院心血管内科主治医师 2020.07-至今 武汉大学人民医院心血管内科副主任医师 |
|
| 成果获奖 | |
|
1.《自主神经再平衡防治心律失常的调控策略与临床转化》2018年湖北省科技进步奖一等奖 2.《高血压及其合并症的免疫机制与防治策略创新》2022年湖北省科技进步奖二等奖 |
|
| 代表性论著 | |
|
1.Zhao M, Zheng Z, Yin Z, Zhang J, Qin J, Wan J,
Wang M. Resolvin D2 and its receptor GPR18 in cardiovascular and metabolic
diseases: a promising biomarker and therapeutic target[J]. Pharmacol Res,
2023:106832.（通讯作者） 2.Zhang J, Ding W, Liu J, Wan J, Wang M. Scavenger Receptors in Myocardial Infarction and Ischemia/Reperfusion Injury: The Potential for Disease Evaluation and Therapy[J]. J Am Heart Assoc, 2023, 12(2):e027862.（通讯作者） 3.Wang M, Zhao M, Xu S, Zheng Z, Zhang J, Pan W, Yin Z, Liu J, Wei C, Wan J, Xu Y. TRPA1 deficiency attenuates cardiac fibrosis via regulating GRK5/NFAT signaling in diabetic rats[J]. Biochem Pharmacol, 2023:115671.（第一作者） 4.Wang M, Zhang J, Yin Z, Ding W, Zhao M, Liu J, Xu Y, Xu S, Pan W, Wei C, Jiang H, Wan J. Microglia-Mediated Neuroimmune Response Regulates Cardiac Remodeling After Myocardial Infarction[J]. J Am Heart Assoc, 2023, 12(12):e029053.（第一作者） 5.Zhao M, Zheng Z, Li C, Wan J, Wang M. Developmental endothelial locus-1 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target[J]. Front Immunol, 2022, 13:1053175.（通讯作者） 6.Zhang J, Ding W, Zhao M, Liu J, Xu Y, Wan J, Wang M. Mechanisms of efferocytosis in determining inflammation resolution: Therapeutic potential and the association with cardiovascular disease[J]. Br J Pharmacol, 2022.（通讯作者） 7.Wang M, Zhao M, Yu J, Xu Y, Zhang J, Liu J, Zheng Z, Ye J, Wang Z, Ye D, Feng Y, Xu S, Pan W, Wei C, Wan J. MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice[J]. Front Cardiovasc Med, 2022, 9:727474.（第一作者） 8.Wang M, Zhang J, Zhao M, Liu J, Ye J, Xu Y, Wang Z, Ye D, Li D, Wan J. Resolvin D1 Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Inflammation, Oxidative and Endoplasmic Reticulum Stress[J]. Front Pharmacol, 2022, 12:749899.（第一作者） 9.Wang M, Liu M, Zhang J, Liu J, Ye J, Xu Y, Wang Z, Ye D, Zhao M, Wan J. Resolvin D1 protects against sepsis-induced cardiac injury in mice[J]. Biofactors, 2020.（第一作者） 10.Pan W, Zhang J, Wang M, Ye J, Xu Y, Shen B, He H, Wang Z, Ye D, Zhao M, Luo Z, Liu M, Zhang P, Gu J, Liu M, Li D, Liu J, Wan J. Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients[J]. Hypertension, 2020:Hypertensionaha12015289.（共同第一作者） |
| Name | Menglong Wang |
| Date of birth | November, 1989 |
| Department | Department of Cardiology, Renmin Hospital of Wuhan University |
| Title | Associate Chief Physician, Master tutor |
| whuwangmenglong@163.com | |
| TEL | 15827526356 |
| Research Direction | |
|
1. The role and mechanism of inflammation
resolution in cardiovascular diseases 2. The mechanism underlying the regulatory effects of central neuroimmune response in cardiovascular diseases |
|
| Personal Profile | |
| Dr. Wang is mainly engaged in basic and clinical research in cardiovascular diseases. Dr. Wang presided one youth foundation of National Natural Science Foundation of China, one Hubei Natural Science Foundation project, one Central University Basic Research Fund project, and participated in more than 10 projects. Dr. Wang published more than 30 papers as the first (including co-first) and corresponding (including co-corresponding) author. Dr. Wang has won one first prize and one second prize of Science and Technology Progress Award of Hubei Province. | |
| Selected Publications | |
|
1.Zhao M, Zheng Z, Yin Z, Zhang J, Qin J, Wan J,
Wang M. Resolvin D2 and its receptor GPR18 in cardiovascular and metabolic
diseases: a promising biomarker and therapeutic target[J]. Pharmacol Res,
2023:106832. (corresponding author) 2.Zhang J, Ding W, Liu J, Wan J, Wang M. Scavenger Receptors in Myocardial Infarction and Ischemia/Reperfusion Injury: The Potential for Disease Evaluation and Therapy[J]. J Am Heart Assoc, 2023, 12(2):e027862. (corresponding author) 3.Wang M, Zhao M, Xu S, Zheng Z, Zhang J, Pan W, Yin Z, Liu J, Wei C, Wan J, Xu Y. TRPA1 deficiency attenuates cardiac fibrosis via regulating GRK5/NFAT signaling in diabetic rats[J]. Biochem Pharmacol, 2023:115671. (first author) 4.Wang M, Zhang J, Yin Z, Ding W, Zhao M, Liu J, Xu Y, Xu S, Pan W, Wei C, Jiang H, Wan J. Microglia-Mediated Neuroimmune Response Regulates Cardiac Remodeling After Myocardial Infarction[J]. J Am Heart Assoc, 2023, 12(12):e029053. (first author) 5.Zhao M, Zheng Z, Li C, Wan J, Wang M. Developmental endothelial locus-1 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target[J]. Front Immunol, 2022, 13:1053175. (corresponding author) 6.Zhang J, Ding W, Zhao M, Liu J, Xu Y, Wan J, Wang M. Mechanisms of efferocytosis in determining inflammation resolution: Therapeutic potential and the association with cardiovascular disease[J]. Br J Pharmacol, 2022. (corresponding author) 7.Wang M, Zhao M, Yu J, Xu Y, Zhang J, Liu J, Zheng Z, Ye J, Wang Z, Ye D, Feng Y, Xu S, Pan W, Wei C, Wan J. MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice[J]. Front Cardiovasc Med, 2022, 9:727474. (first author) 8.Wang M, Zhang J, Zhao M, Liu J, Ye J, Xu Y, Wang Z, Ye D, Li D, Wan J. Resolvin D1 Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Inflammation, Oxidative and Endoplasmic Reticulum Stress[J]. Front Pharmacol, 2022, 12:749899. (first author) 9.Wang M, Liu M, Zhang J, Liu J, Ye J, Xu Y, Wang Z, Ye D, Zhao M, Wan J. Resolvin D1 protects against sepsis-induced cardiac injury in mice[J]. Biofactors, 2020. (first author) 10.Pan W, Zhang J, Wang M, Ye J, Xu Y, Shen B, He H, Wang Z, Ye D, Zhao M, Luo Z, Liu M, Zhang P, Gu J, Liu M, Li D, Liu J, Wan J. Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients[J]. Hypertension, 2020:Hypertensionaha12015289. (co-first author) |
武汉大学人民医院
湖北省人民医院